Clinical trials: Multiple Sclerosis Relapsing Remitting
Multiple Sclerosis
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Primary Aims: To determine how effective long term Natalizumab (NTZ) therapy is in slowing the progression of whole brain atrophy.
- Trial name
- NCT02588053
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis, Relapsing-Remitting
RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS
A randomized trial of long-term dosage of rituximab in multiple sclerosis
- Trial name
- RIDOSE-MS (NCT03979456)
- Testing
- Rituximab
- Where
- 17 sites in Sweden
- Volunteers
- 200 people
- Sponsor
- Karolinska Institutet
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis
Idiopathic inflammatory disorders of the central nervous system include various disorders of which multiple sclerosis is the most common.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Controls, Multiple Sclerosis
- Trial name
- AMIS (NCT04201470)
- Testing
- Blood withdrawal, MRI, Neurologic / neuropsychologic tests - Patients
- Where
- France
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
The Effect of Virtual Reality on Fatigue and Functional Capacity in Patients With MS
This clinical trial aims to evaluate the effectiveness of virtual reality (VR) as a complementary intervention to traditional physical therapy for individuals diagnosed with Multiple Sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Virtual Reality
- Trial name
- VRMS (NCT06987994)
- Testing
- control group( physical therapy), Experemental group
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istinye University
Multiple Sclerosis, Relapsing-Remitting
Efficacy of Diet on Quality of Life in Multiple Sclerosis
The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care.
- Trial name
- EDQ (NCT05007483)
- Testing
- BodyBio Balance Oil, Kirunal Fish Oil, BodyBio PC
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Terry L. Wahls
Multiple Sclerosis (MS) - Relapsing-remitting
Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity
Reference MRI scan is recommended 6 months after treatment onset in patients with multiple sclerosis (MS), and follow-up scans at 12 months later to monitor subclinical activity.
- Trial name
- MoMo-NfL (NCT07292480)
- Testing
- Monthly pNfL monitoring
- Where
- 2 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Relapsing-remitting Multiple Sclerosis
The HIt HArd and hiT Early in Multiple Sclerosis Trial
The HiHat trial is a Phase 2 study aimed at evaluating the safety and feasibility of sequential treatment with rituximab and cladribine in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- HiHat (NCT07517185)
- Testing
- Sequential treatment with rituximab and cladribine
- Where
- 4 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Uppsala University
Multiple Sclerosis
Wahls Paleo Diet and Progressive Multiple Sclerosis
Based on favorable preliminary data from ongoing studies testing the safety and tolerability of a nutrition, exercise and neuromuscular electrical stimulation funded by Direct MS, the investigators are proposing a pilot study…
- Trial name
- NCT01915433
- Testing
- Wahls Paleo Plus, Wahls Diet
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Terry L. Wahls
Multiple Sclerosis
VALIDATE: Factor VIII Trending for MS Relapse
Multiple sclerosis (MS) patients hospitalized with an acute motor or visual relapse will be consented. Factor VIII-related labs will be systematically drawn for six months.
- Trial name
- NCT04082468
- Testing
- Blood sample collection for coagulation profile
- Where
- United States
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Relapsing-Remitting Multiple Sclerosis
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
This was an observational, single arm, multicentric study conducted for the adjustment of treatment strategy and its monitoring using high-frequency and high-dosage administration of interferon-beta (Rebif) in MS subjects.
- Trial name
- NCT01142453
- Testing
- Interferon beta 1a
- Volunteers
- 231 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing Remitting Multiple Sclerosis
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Primary Objective: To evaluate long-term safety of alemtuzumab. Secondary Objectives: To evaluate long term efficacy of alemtuzumab.
- Trial name
- TOPAZ (NCT02255656)
- Testing
- alemtuzumab GZ402673
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 1,062 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
Cellular microRNA Signatures in Multiple Sclerosis
A limited number of studies on microRNA expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- SEP-MIR (NCT05290688)
- Testing
- 50 ml blodd sampling
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut Pasteur
Relapsing-remitting Multiple Sclerosis
Development of a Motivational Intervention to Improve Treatment Adherence in MS
As many as 50% of MS patients prematurely discontinue their disease modifying medications. For this study, we will develop a telephone-based talk therapy intervention and then conduct a randomized controlled trial.
- Trial name
- MIMS (NCT01925690)
- Testing
- Motivational Interviewing-Cognitive Behavioral Therapy, Brief Education
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Missouri, Kansas City
Multiple Sclerosis, Relapsing-Remitting
Tecfidera and the Gut Microbiota
The primary objective of the study is to determine if dimethyl fumarate (DMF) causes changes in the abundance and diversity of commensal microbiota.
- Trial name
- TECONGUT (NCT02471560)
- Testing
- dimethyl fumarate, injectable MS DMT
- Where
- 7 sites in Norway
- Volunteers
- 36 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability…
- Trial name
- NCT03093324
- Testing
- ALKS 8700, Dimethyl Fumarate
- Where
- 67 sites in United States, Germany and 1 more
- Volunteers
- 506 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting, Relapsing-Remitting Multiple Sclerosis
Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) as their…
- Trial name
- IMPROVE (NCT02323269)
- Testing
- dimethyl fumarate
- Where
- 10 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Biogen
Multiple Sclerosis
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its clinical effect in the Hispanics with MS given that clinical studies had limited representation of this population.
- Trial name
- NCT01592097
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Southern California
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation (aHSCT) in people with highly active relapsing-remitting multiple sclerosis.
- Trial name
- MS-ACT (NCT06567197)
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Sclerosis, Relapsing-Remitting
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.
- Trial name
- NCT00228397
- Testing
- CCI-779
- Volunteers
- 221 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multiple Sclerosis
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
The purpose of this trial is to evaluate the effects of Rebif® 44 mcg subcutaneous (sc) three times a week (tiw) on a) remyelination/demyelination, b) lesion and brain volume, c) central nervous system (CNS) iron deposition, and…
- Trial name
- NCT01085318
- Testing
- Rebif
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- EMD Serono